IBDEI03F ; ; 19-NOV-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,4165,1,5,0)
 ;;=5^Varicose Veins
 ;;^UTILITY(U,$J,358.3,4165,2)
 ;;=^125410
 ;;^UTILITY(U,$J,358.3,4166,0)
 ;;=454.2^^28^246^88
 ;;^UTILITY(U,$J,358.3,4166,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4166,1,4,0)
 ;;=4^454.2
 ;;^UTILITY(U,$J,358.3,4166,1,5,0)
 ;;=5^Varicose Veins w/Ulcer&Inflam
 ;;^UTILITY(U,$J,358.3,4166,2)
 ;;=^269821
 ;;^UTILITY(U,$J,358.3,4167,0)
 ;;=426.10^^28^246^3
 ;;^UTILITY(U,$J,358.3,4167,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4167,1,4,0)
 ;;=4^426.10
 ;;^UTILITY(U,$J,358.3,4167,1,5,0)
 ;;=5^AV CONDUCTION ABNORMAL
 ;;^UTILITY(U,$J,358.3,4167,2)
 ;;=^11396
 ;;^UTILITY(U,$J,358.3,4168,0)
 ;;=396.8^^28^246^2
 ;;^UTILITY(U,$J,358.3,4168,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4168,1,4,0)
 ;;=4^396.8
 ;;^UTILITY(U,$J,358.3,4168,1,5,0)
 ;;=5^AORTIC/MITRAL STENOSIS/REGURG
 ;;^UTILITY(U,$J,358.3,4168,2)
 ;;=^269584
 ;;^UTILITY(U,$J,358.3,4169,0)
 ;;=414.00^^28^246^19
 ;;^UTILITY(U,$J,358.3,4169,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4169,1,4,0)
 ;;=4^414.00
 ;;^UTILITY(U,$J,358.3,4169,1,5,0)
 ;;=5^CAD
 ;;^UTILITY(U,$J,358.3,4169,2)
 ;;=^28512
 ;;^UTILITY(U,$J,358.3,4170,0)
 ;;=425.4^^28^246^23
 ;;^UTILITY(U,$J,358.3,4170,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4170,1,4,0)
 ;;=4^425.4
 ;;^UTILITY(U,$J,358.3,4170,1,5,0)
 ;;=5^CARDIOMYOPATHY
 ;;^UTILITY(U,$J,358.3,4170,2)
 ;;=^87808
 ;;^UTILITY(U,$J,358.3,4171,0)
 ;;=410.90^^28^246^64
 ;;^UTILITY(U,$J,358.3,4171,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4171,1,4,0)
 ;;=4^410.90
 ;;^UTILITY(U,$J,358.3,4171,1,5,0)
 ;;=5^MYOCARDIAL INFARCTION
 ;;^UTILITY(U,$J,358.3,4171,2)
 ;;=^269673
 ;;^UTILITY(U,$J,358.3,4172,0)
 ;;=427.2^^28^246^69
 ;;^UTILITY(U,$J,358.3,4172,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4172,1,4,0)
 ;;=4^427.2
 ;;^UTILITY(U,$J,358.3,4172,1,5,0)
 ;;=5^PAROX ATR TACHYCARDIA
 ;;^UTILITY(U,$J,358.3,4172,2)
 ;;=^117073
 ;;^UTILITY(U,$J,358.3,4173,0)
 ;;=272.4^^28^246^60
 ;;^UTILITY(U,$J,358.3,4173,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4173,1,4,0)
 ;;=4^272.4
 ;;^UTILITY(U,$J,358.3,4173,1,5,0)
 ;;=5^Hyperlipidemia, NOS
 ;;^UTILITY(U,$J,358.3,4173,2)
 ;;=^87281
 ;;^UTILITY(U,$J,358.3,4174,0)
 ;;=410.71^^28^246^5
 ;;^UTILITY(U,$J,358.3,4174,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4174,1,4,0)
 ;;=4^410.71
 ;;^UTILITY(U,$J,358.3,4174,1,5,0)
 ;;=5^Acute Non-ST Elev MI (NSTEMI)
 ;;^UTILITY(U,$J,358.3,4174,2)
 ;;=^269667
 ;;^UTILITY(U,$J,358.3,4175,0)
 ;;=410.91^^28^246^4
 ;;^UTILITY(U,$J,358.3,4175,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4175,1,4,0)
 ;;=4^410.91
 ;;^UTILITY(U,$J,358.3,4175,1,5,0)
 ;;=5^Acute Myocardial Infarction NOS
 ;;^UTILITY(U,$J,358.3,4175,2)
 ;;=^269674
 ;;^UTILITY(U,$J,358.3,4176,0)
 ;;=414.05^^28^246^22
 ;;^UTILITY(U,$J,358.3,4176,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4176,1,4,0)
 ;;=4^414.05
 ;;^UTILITY(U,$J,358.3,4176,1,5,0)
 ;;=5^CAD,Occlusion of Venous Graft NOS
 ;;^UTILITY(U,$J,358.3,4176,2)
 ;;=^304308
 ;;^UTILITY(U,$J,358.3,4177,0)
 ;;=271.3^^28^247^11
 ;;^UTILITY(U,$J,358.3,4177,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4177,1,4,0)
 ;;=4^271.3
 ;;^UTILITY(U,$J,358.3,4177,1,5,0)
 ;;=5^Glucose Intolerance
 ;;^UTILITY(U,$J,358.3,4177,2)
 ;;=^64790
 ;;^UTILITY(U,$J,358.3,4178,0)
 ;;=611.1^^28^247^16
 ;;^UTILITY(U,$J,358.3,4178,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4178,1,4,0)
 ;;=4^611.1
 ;;^UTILITY(U,$J,358.3,4178,1,5,0)
 ;;=5^Gynecomastia
 ;;^UTILITY(U,$J,358.3,4178,2)
 ;;=^60454
 ;;^UTILITY(U,$J,358.3,4179,0)
 ;;=704.1^^28^247^17
 ;;^UTILITY(U,$J,358.3,4179,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4179,1,4,0)
 ;;=4^704.1
 ;;^UTILITY(U,$J,358.3,4179,1,5,0)
 ;;=5^Hirsutism
 ;;^UTILITY(U,$J,358.3,4179,2)
 ;;=^57407
 ;;^UTILITY(U,$J,358.3,4180,0)
 ;;=251.2^^28^247^27
 ;;^UTILITY(U,$J,358.3,4180,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4180,1,4,0)
 ;;=4^251.2
 ;;^UTILITY(U,$J,358.3,4180,1,5,0)
 ;;=5^Hypoglycemia NOS
 ;;^UTILITY(U,$J,358.3,4180,2)
 ;;=^60580
 ;;^UTILITY(U,$J,358.3,4181,0)
 ;;=257.2^^28^247^28
 ;;^UTILITY(U,$J,358.3,4181,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4181,1,4,0)
 ;;=4^257.2
 ;;^UTILITY(U,$J,358.3,4181,1,5,0)
 ;;=5^Hypogonadism,Male
 ;;^UTILITY(U,$J,358.3,4181,2)
 ;;=^88213
 ;;^UTILITY(U,$J,358.3,4182,0)
 ;;=253.2^^28^247^31
 ;;^UTILITY(U,$J,358.3,4182,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4182,1,4,0)
 ;;=4^253.2
 ;;^UTILITY(U,$J,358.3,4182,1,5,0)
 ;;=5^Hypopituitarism
 ;;^UTILITY(U,$J,358.3,4182,2)
 ;;=^60686
 ;;^UTILITY(U,$J,358.3,4183,0)
 ;;=733.00^^28^247^40
 ;;^UTILITY(U,$J,358.3,4183,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4183,1,4,0)
 ;;=4^733.00
 ;;^UTILITY(U,$J,358.3,4183,1,5,0)
 ;;=5^Osteoporosis NOS
 ;;^UTILITY(U,$J,358.3,4183,2)
 ;;=^87159
 ;;^UTILITY(U,$J,358.3,4184,0)
 ;;=278.00^^28^247^37
 ;;^UTILITY(U,$J,358.3,4184,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4184,1,4,0)
 ;;=4^278.00
 ;;^UTILITY(U,$J,358.3,4184,1,5,0)
 ;;=5^Obesity
 ;;^UTILITY(U,$J,358.3,4184,2)
 ;;=^84823
 ;;^UTILITY(U,$J,358.3,4185,0)
 ;;=278.01^^28^247^36
 ;;^UTILITY(U,$J,358.3,4185,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4185,1,4,0)
 ;;=4^278.01
 ;;^UTILITY(U,$J,358.3,4185,1,5,0)
 ;;=5^Morbid Obesity
 ;;^UTILITY(U,$J,358.3,4185,2)
 ;;=^84844
 ;;^UTILITY(U,$J,358.3,4186,0)
 ;;=250.80^^28^247^5
 ;;^UTILITY(U,$J,358.3,4186,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4186,1,4,0)
 ;;=4^250.80
 ;;^UTILITY(U,$J,358.3,4186,1,5,0)
 ;;=5^DM Type II w/ LE Ulcer
 ;;^UTILITY(U,$J,358.3,4186,2)
 ;;=DM Type II with LE Ulcer^267846^707.10
 ;;^UTILITY(U,$J,358.3,4187,0)
 ;;=250.00^^28^247^3
 ;;^UTILITY(U,$J,358.3,4187,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4187,1,4,0)
 ;;=4^250.00
 ;;^UTILITY(U,$J,358.3,4187,1,5,0)
 ;;=5^DM Typ II w/o Complications
 ;;^UTILITY(U,$J,358.3,4187,2)
 ;;=^33605
 ;;^UTILITY(U,$J,358.3,4188,0)
 ;;=250.40^^28^247^6
 ;;^UTILITY(U,$J,358.3,4188,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4188,1,4,0)
 ;;=4^250.40
 ;;^UTILITY(U,$J,358.3,4188,1,5,0)
 ;;=5^DM Type II w/ Nephropathy
 ;;^UTILITY(U,$J,358.3,4188,2)
 ;;=^267837^583.81
 ;;^UTILITY(U,$J,358.3,4189,0)
 ;;=250.50^^28^247^8
 ;;^UTILITY(U,$J,358.3,4189,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4189,1,4,0)
 ;;=4^250.50
 ;;^UTILITY(U,$J,358.3,4189,1,5,0)
 ;;=5^DM Type II w/ PDR
 ;;^UTILITY(U,$J,358.3,4189,2)
 ;;=DM Type II w/ PDR^267839^362.02
 ;;^UTILITY(U,$J,358.3,4190,0)
 ;;=250.60^^28^247^7
 ;;^UTILITY(U,$J,358.3,4190,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4190,1,4,0)
 ;;=4^250.60
 ;;^UTILITY(U,$J,358.3,4190,1,5,0)
 ;;=5^DM Type II w/ Neuropathy
 ;;^UTILITY(U,$J,358.3,4190,2)
 ;;=^267841^357.2
 ;;^UTILITY(U,$J,358.3,4191,0)
 ;;=250.70^^28^247^9
 ;;^UTILITY(U,$J,358.3,4191,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4191,1,4,0)
 ;;=4^250.70
 ;;^UTILITY(U,$J,358.3,4191,1,5,0)
 ;;=5^DM Type II w/ Peripheral Vasc Dis
 ;;^UTILITY(U,$J,358.3,4191,2)
 ;;=^267843^443.81
 ;;^UTILITY(U,$J,358.3,4192,0)
 ;;=250.01^^28^247^4
 ;;^UTILITY(U,$J,358.3,4192,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4192,1,4,0)
 ;;=4^250.01
 ;;^UTILITY(U,$J,358.3,4192,1,5,0)
 ;;=5^DM Type I w/o Complications
 ;;^UTILITY(U,$J,358.3,4192,2)
 ;;=^33586
 ;;^UTILITY(U,$J,358.3,4193,0)
 ;;=272.0^^28^247^21
 ;;^UTILITY(U,$J,358.3,4193,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4193,1,4,0)
 ;;=4^272.0
 ;;^UTILITY(U,$J,358.3,4193,1,5,0)
 ;;=5^Hypercholesterolemia, Pure
 ;;^UTILITY(U,$J,358.3,4193,2)
 ;;=Hypercholesterolemia, Pure^59973
 ;;^UTILITY(U,$J,358.3,4194,0)
 ;;=272.1^^28^247^25
 ;;^UTILITY(U,$J,358.3,4194,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4194,1,4,0)
 ;;=4^272.1
 ;;^UTILITY(U,$J,358.3,4194,1,5,0)
 ;;=5^Hypertriglyceridemia, Pure
 ;;^UTILITY(U,$J,358.3,4194,2)
 ;;=Hypertriglyceridemia, Pure^101303
 ;;^UTILITY(U,$J,358.3,4195,0)
 ;;=275.42^^28^247^20
 ;;^UTILITY(U,$J,358.3,4195,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4195,1,4,0)
 ;;=4^275.42
 ;;^UTILITY(U,$J,358.3,4195,1,5,0)
 ;;=5^Hypercalcemia
 ;;^UTILITY(U,$J,358.3,4195,2)
 ;;=^59932
 ;;^UTILITY(U,$J,358.3,4196,0)
 ;;=275.41^^28^247^26
 ;;^UTILITY(U,$J,358.3,4196,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4196,1,4,0)
 ;;=4^275.41
 ;;^UTILITY(U,$J,358.3,4196,1,5,0)
 ;;=5^Hypocalcemia
 ;;^UTILITY(U,$J,358.3,4196,2)
 ;;=^60542
 ;;^UTILITY(U,$J,358.3,4197,0)
 ;;=276.7^^28^247^22
 ;;^UTILITY(U,$J,358.3,4197,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4197,1,4,0)
 ;;=4^276.7
 ;;^UTILITY(U,$J,358.3,4197,1,5,0)
 ;;=5^Hyperkalemia
 ;;^UTILITY(U,$J,358.3,4197,2)
 ;;=^60042
 ;;^UTILITY(U,$J,358.3,4198,0)
 ;;=275.2^^28^247^18
 ;;^UTILITY(U,$J,358.3,4198,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4198,1,4,0)
 ;;=4^275.2
 ;;^UTILITY(U,$J,358.3,4198,1,5,0)
 ;;=5^Hyper Or Hypomagnesemia
 ;;^UTILITY(U,$J,358.3,4198,2)
 ;;=^35626
 ;;^UTILITY(U,$J,358.3,4199,0)
 ;;=276.0^^28^247^23
 ;;^UTILITY(U,$J,358.3,4199,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4199,1,4,0)
 ;;=4^276.0
 ;;^UTILITY(U,$J,358.3,4199,1,5,0)
 ;;=5^Hypernatremia
 ;;^UTILITY(U,$J,358.3,4199,2)
 ;;=^60144
 ;;^UTILITY(U,$J,358.3,4200,0)
 ;;=276.1^^28^247^29
 ;;^UTILITY(U,$J,358.3,4200,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4200,1,4,0)
 ;;=4^276.1
 ;;^UTILITY(U,$J,358.3,4200,1,5,0)
 ;;=5^Hyponatremia
 ;;^UTILITY(U,$J,358.3,4200,2)
 ;;=Hyponatremia^60722
 ;;^UTILITY(U,$J,358.3,4201,0)
 ;;=275.3^^28^247^19
 ;;^UTILITY(U,$J,358.3,4201,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4201,1,4,0)
 ;;=4^275.3
 ;;^UTILITY(U,$J,358.3,4201,1,5,0)
 ;;=5^Hyper Or Hypophosphatemia
 ;;^UTILITY(U,$J,358.3,4201,2)
 ;;=^93796
 ;;^UTILITY(U,$J,358.3,4202,0)
 ;;=240.0^^28^247^14
 ;;^UTILITY(U,$J,358.3,4202,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4202,1,4,0)
 ;;=4^240.0
 ;;^UTILITY(U,$J,358.3,4202,1,5,0)
 ;;=5^Goiter, Simple
 ;;^UTILITY(U,$J,358.3,4202,2)
 ;;=^259806
 ;;^UTILITY(U,$J,358.3,4203,0)
 ;;=241.1^^28^247^13
 ;;^UTILITY(U,$J,358.3,4203,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,4203,1,4,0)
 ;;=4^241.1
 ;;^UTILITY(U,$J,358.3,4203,1,5,0)
 ;;=5^Goiter, Nontox, Multinod
